



## **Cumberland Pharmaceuticals to Present at the 2011 UBS Global Specialty Pharmaceuticals Conference in London**

NASHVILLE, Tenn., May 11, 2011 /PRNewswire/ -- **Cumberland Pharmaceuticals Inc.** (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the 2011 UBS Global Specialty Pharmaceuticals Conference in London on Wednesday, May 25, 2011, at 12:30 p.m.

The presentation will be simultaneously webcast and can be accessed by visiting the Investor Relations section of Cumberland Pharmaceuticals' website at [www.cumberlandpharma.com](http://www.cumberlandpharma.com).

Shortly following the live webcast a replay will also be available on the Company's website.

### **About Cumberland Pharmaceuticals**

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote® for the treatment of acetaminophen poisoning, Caldolor®, the first injectable treatment for pain and fever approved in the United States, and Kristalose®, a prescription laxative. Cumberland is dedicated to providing innovative products which improve quality of care for patients. For more information, please visit the Company website at [www.cumberlandpharma.com](http://www.cumberlandpharma.com).

SOURCE Cumberland Pharmaceuticals Inc.

News Provided by Acquire Media